Overview

Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is the safety and efficacy of Trastuzumab plus natural killer(NK) immunotherapy to recurrent breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborator:
Shenzhen Hank Bioengineering Institute
Treatments:
Trastuzumab